Jifeng Yu

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 47

Top Topics

Acute Myeloid Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

Expert opinion on biological therapy

Biomarker research

Scientific reports

This page only lists publications with an associated author ORCID identifier.

Publications

Lijie Han, Haizhou Xing, Weijie Cao, Yongping Song, Zhongxing Jiang, Jifeng Yu
Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting. Expert opinion on biological therapy 24 (4) (2024)
Tongcheng Dai, Hao Sun, Tyler Liban, Ildefonso Vicente-Suarez, Bin Zhang, Yongping Song, Zhongxing Jiang, Jifeng Yu, Jackie Sheng, Binhua Lv
A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody. Scientific reports 14 (1) (2024)
Hao Sun, Haizhou Xing, Lijie Han, Yongping Song, Zhongxing Jiang, Yanyan Liu, Jifeng Yu
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting. Expert opinion on biological therapy (2024)
Xingchen Li, Wenzhi Tian, Zhongxing Jiang, Yongping Song, Xiangyang Leng, Jifeng Yu
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions. Cancer immunology, immunotherapy : CII 73 (2) (2024)
Xingchen Li, Wenzhi Tian, Zhongxing Jiang, Yongping Song, Xiangyang Leng, Jifeng Yu
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions. Cancer immunology, immunotherapy : CII 73 (2) (2024)
Lijie Han, Haizhou Xing, Weijie Cao, Yongping Song, Zhongxing Jiang, Jifeng Yu
Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting. Expert opinion on biological therapy 24 (4) (2024)
Peng Zhang, Xinyuan Liu, Zhuoyu Gu, Zhongxing Jiang, Song Zhao, Yongping Song, Jifeng Yu
Targeting TIGIT for cancer immunotherapy: recent advances and future directions. Biomarker research 12 (1) (2024)
Peng Zhang, Xinyuan Liu, Zhuoyu Gu, Zhongxing Jiang, Song Zhao, Yongping Song, Jifeng Yu
Targeting TIGIT for cancer immunotherapy: recent advances and future directions. Biomarker research 12 (1) (2024)
Xingchen Li, Wenzhi Tian, Zhongxing Jiang, Yongping Song, Xiangyang Leng, Jifeng Yu
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions. Cancer immunology, immunotherapy : CII 73 (2) (2024)
Tongcheng Dai, Hao Sun, Tyler Liban, Ildefonso Vicente-Suarez, Bin Zhang, Yongping Song, Zhongxing Jiang, Jifeng Yu, Jackie Sheng, Binhua Lv
A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody. Scientific reports 14 (1) (2024)
Xingchen Li, Wenzhi Tian, Zhongxing Jiang, Yongping Song, Xiangyang Leng, Jifeng Yu
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions. Cancer immunology, immunotherapy : CII 73 (2) (2024)
Lijie Han, Haizhou Xing, Weijie Cao, Yongping Song, Zhongxing Jiang, Jifeng Yu
Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65 th American Society of Hematology 2023 annual meeting. Expert opinion on biological therapy (2024)
Xingchen Li, Wenzhi Tian, Zhongxing Jiang, Yongping Song, Xiangyang Leng, Jifeng Yu
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions. Cancer immunology, immunotherapy : CII 73 (2) (2024)
Tongcheng Dai, Hao Sun, Tyler Liban, Ildefonso Vicente-Suarez, Bin Zhang, Yongping Song, Zhongxing Jiang, Jifeng Yu, Jackie Sheng, Binhua Lv
A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody. Scientific reports 14 (1) (2024)
Lijie Han, Haizhou Xing, Weijie Cao, Yongping Song, Zhongxing Jiang, Jifeng Yu
Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting. Expert opinion on biological therapy (2024)
Hao Sun, Haizhou Xing, Lijie Han, Yongping Song, Zhongxing Jiang, Yanyan Liu, Jifeng Yu
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting. Expert opinion on biological therapy (2024)
Hao Sun, Haizhou Xing, Lijie Han, Yongping Song, Zhongxing Jiang, Yanyan Liu, Jifeng Yu
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting. Expert opinion on biological therapy 24 (5) (2024)
Tongcheng Dai, Hao Sun, Tyler Liban, Ildefonso Vicente-Suarez, Bin Zhang, Yongping Song, Zhongxing Jiang, Jifeng Yu, Jackie Sheng, Binhua Lv
A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody. Scientific reports 14 (1) (2024)
Hao Sun, Haizhou Xing, Lijie Han, Yongping Song, Zhongxing Jiang, Yanyan Liu, Jifeng Yu
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting. Expert opinion on biological therapy 24 (5) (2024)
Tongcheng Dai, Hao Sun, Tyler Liban, Ildefonso Vicente-Suarez, Bin Zhang, Yongping Song, Zhongxing Jiang, Jifeng Yu, Jackie Sheng, Binhua Lv
A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody. Scientific reports 14 (1) (2024)
Lingling Liu, Qiuhao Fu, Danfeng Zhang, Dandan Chen, Fang Wang, Rong Guo, Xinsheng Xie, Zhongxing Jiang, Jifeng Yu, Yingmei Li
Analysis of Mean Corpuscular Volume and Red Cell Distribution Width in Patients with Aplastic Anemia. Hemoglobin (2023)
Song Li, Dianze Chen, Huiqin Guo, Yanan Yang, Dandan Liu, Chunmei Yang, Xing Bai, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Yongping Song, Zhongxing Jiang, Ruliang Zhang, Jifeng Yu, Wenzhi Tian
IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy. Antibody therapeutics 6 (4) (2023)
Xingchen Li, Peng Zhang, Hao Sun, Lijie Han, Zhongxing Jiang, Jifeng Yu
Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting. Expert opinion on biological therapy (2023)
Qiaoqiao Li, Chunyan Liang, Xintong Xu, Congli Zhang, Weijie Cao, Meng Wang, Zhongxing Jiang, Haizhou Xing, Jifeng Yu
CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia. Leukemia & lymphoma 63 (9) (2022)
Hao Sun, Yingmei Li, Peng Zhang, Haizhou Xing, Song Zhao, Yongping Song, Dingming Wan, Jifeng Yu
Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives. Biomarker research 10 (1) (2022)
Jifeng Yu, Song Li, Dianze Chen, Dandan Liu, Huiqin Guo, Chunmei Yang, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Xing Bai, Yongping Song, Zhongxing Jiang, Ruliang Zhang, Wenzhi Tian
IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells. Leukemia 37 (3) (2022)
Jifeng Yu, Song Li, Dianze Chen, Dandan Liu, Huiqin Guo, Chunmei Yang, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Xing Bai, Yongping Song, Zhongxing Jiang, Ruliang Zhang, Wenzhi Tian
IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells. Leukemia 37 (3) (2022)
Danfeng Zhang, Jifeng Yu, Lingling Liu, Fang Wang, Shujuan Wang, Xinsheng Xie, Yingmei Li, Zhongxing Jiang
Acute arrest of hemopoiesis presenting as severe aplastic anemia: a retrospective analysis. Hematology (Amsterdam, Netherlands) 26 (1) (2022)
Jifeng Yu, Song Li, Dianze Chen, Dandan Liu, Huiqin Guo, Chunmei Yang, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Xing Bai, Yongping Song, Zhongxing Jiang, Ruliang Zhang, Wenzhi Tian
IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells. Leukemia 37 (3) (2022)
Weijie Cao, Xiaoning Li, Ran Zhang, Zhilei Bian, Suping Zhang, Li Li, Haizhou Xing, Changfeng Liu, Xinsheng Xie, Zhongxing Jiang, Xiaosheng Fang, Dingming Wan, Jifeng Yu
Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation. Scientific reports 12 (1) (2022)
Jifeng Yu, Song Li, Dianze Chen, Dandan Liu, Huiqin Guo, Chunmei Yang, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Xing Bai, Yongping Song, Zhongxing Jiang, Ruliang Zhang, Wenzhi Tian
IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells. Leukemia 37 (3) (2022)
Jifeng Yu, Song Li, Dianze Chen, Dandan Liu, Huiqin Guo, Chunmei Yang, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Xing Bai, Yongping Song, Zhongxing Jiang, Ruliang Zhang, Wenzhi Tian
IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells. Leukemia 37 (3) (2022)
Hao Sun, Yingmei Li, Peng Zhang, Haizhou Xing, Song Zhao, Yongping Song, Dingming Wan, Jifeng Yu
Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives. Biomarker research 10 (1) (2022)
Jifeng Yu, Song Li, Dianze Chen, Dandan Liu, Huiqin Guo, Chunmei Yang, Wei Zhang, Li Zhang, Gui Zhao, Xiaoping Tu, Liang Peng, Sijin Liu, Xing Bai, Yongping Song, Zhongxing Jiang, Ruliang Zhang, Wenzhi Tian
IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells. Leukemia (2022)
Hao Sun, Yingmei Li, Peng Zhang, Haizhou Xing, Song Zhao, Yongping Song, Dingming Wan, Jifeng Yu
Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives. Biomarker research 10 (1) (2022)
Hao Sun, Yingmei Li, Peng Zhang, Haizhou Xing, Song Zhao, Yongping Song, Dingming Wan, Jifeng Yu
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives. Biomarker research 10 (1) (2022)
Zhongxing Jiang, Hao Sun, Jifeng Yu, Wenzhi Tian, Yongping Song
Targeting CD47 for cancer immunotherapy. Journal of hematology & oncology 14 (1) (2021)
Suping Zhang, Li Li, Weijie Cao, Yingmei Li, Zhongxing Jiang, Jifeng Yu, Dingming Wan
Donor cell leukemia/myelodysplastic syndrome after allogeneic stem cell transplantation: a rare phenomenon with more challenges for hematologists. Hematology (Amsterdam, Netherlands) 26 (1) (2021)
Xiaoning Li, Weijie Cao, Suping Zhang, Li Li, Yingmei Li, Zhongxing Jiang, Dingming Wan, Jifeng Yu
Philadelphia chromosome-positive B-lymphoblastic lymphoma successfully treated with chemotherapy regimen containing imatinib: A rare case report and literature review. Medicine 100 (23) (2021)
Yingmei Li, Dingming Wan, Rong Guo, Fang Wang, Lijie Han, Danfeng Zhang, Haizhou Xing, Weijie Cao, Yu Liu, Xinsheng Xie, Jifeng Yu, Zhongxing Jiang
Decreased bone marrow regulatory innate lymphoid cells show a distinctive miRNA profiling in aplastic anemia. Hematology (Amsterdam, Netherlands) 26 (1) (2021)
Ehtisham Ul Haq, Jifeng Yu, Jiancheng Guo
Frontiers in the COVID-19 vaccines development. Experimental hematology & oncology 9 (2020)
Jifeng Yu, Yingmei Li, Danfeng Zhang, Dingming Wan, Zhongxing Jiang
Clinical implications of recurrent gene mutations in acute myeloid leukemia. Experimental hematology & oncology 9 (2020)
Jifeng Yu, Hao Sun, Weijie Cao, Lijie Han, Yongping Song, Dingming Wan, Zhongxing Jiang
Applications of gut microbiota in patients with hematopoietic stem-cell transplantation. Experimental hematology & oncology 9 (1) (2020)
Jifeng Yu, Yingmei Li, Tao Li, Yafei Li, Haizhou Xing, Hui Sun, Ling Sun, Dingming Wan, Yanfang Liu, Xinsheng Xie, Zhongxing Jiang
Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia. Experimental hematology & oncology 9 (2020)
Jifeng Yu, Peter Y Z Jiang, Hao Sun, Xia Zhang, Zhongxing Jiang, Yingmei Li, Yongping Song
Advances in targeted therapy for acute myeloid leukemia. Biomarker research 8 (2020)
Jifeng Yu, Yingmei Li, Haizhou Xing, Yue Pan, Hui Sun, Dingming Wan, Yanfang Liu, Xinsheng Xie, Chong Wang, Ling Sun, Kai Sun, Zhongxing Jiang
Clinical Characteristics And Outcome Of Biphenotypic Acute Leukemia: 10 Case Reports And Literature Review. Cancer management and research 11 (2019)
Jifeng Yu, Yingmei Li, Yue Pan, Yu Liu, Haizhou Xing, Xinsheng Xie, Dingming Wan, Zhongxing Jiang
Deficient Regulatory Innate Lymphoid Cells and Differential Expression of miRNAs in Acute Myeloid Leukemia Quantified by Next Generation Sequence. Cancer management and research 11 (2019)